ARTERIAL HYPERTENSION: A HEAVY BURDEN ON THE HEALTHCARE SYSTEM AND THE ROLE OF BETA-BLOCKERS IN RESISTANT HYPERTENSION (LITERATURE REVIEW)
DOI:
https://doi.org/10.52340/jecm.2025.01.05Keywords:
beta-blockers, resistant arterial hypertension, literature reviewAbstract
Hypertension is a major global health concern, affected 2/3 of adult population. According to WHO observational study only 21% of patients achieving adequate blood pressure control worldwide. Hypertension significantly increases cardiovascular risks, including ischemic heart disease, stroke, heart failure, and overall mortality. According meta-analysis, a 10-mmHg reduction in systolic blood pressure leads to 20% reduction in major cardiovascular disease events, 17% reduction in coronary artery disease risk, 27% reduction in stroke risk, 28% reduction in heart failure risk, 13% reduction in overall mortality risk. Resistant hypertension (RHTN), affecting approximately 20-30% of individuals, is defined as uncontrolled blood pressure despite treatment with three antihypertensive agents. Current guidelines recommend adding a fourth agent, such as a beta-blocker, for RHTN. Evidence for beta-blocker use in RHTN is limited, mainly derived from the PATHWAY-2 trial, which showed that bisoprolol reduced systolic blood pressure. However, knowledge gaps exist regarding other beta-blockers, systolic and diastolic blood pressure outcomes, and efficacy in patients with CCB intolerance.
Downloads
References
https://www.who.int/news-room/fact-sheets/detail/hypertension
Wang, Yu, Jun S. Lee, Lisa M. Pollack, Ashutosh Kumar, Sally Honeycutt, and Feijun Luo. "Health Care Expenditures and Use Associated with Hypertension Among US Adults." American journal of preventive medicine 67, no. 6 (2024): 820-831.
Aune, Dagfinn, Wentao Huang, Jing Nie, and Yafeng Wang. "Hypertension and the risk of all‐cause and cause‐specific mortality: an outcome‐wide association study of 67 causes of death in The National Health Interview Survey." BioMed Research International 2021, no. 1 (2021): 9376134
Kaplan, Robert C., Bruce M. Psaty, Susan R. Heckbert, Nicholas L. Smith, and Rozenn N. Lemaitre. "Blood pressure level and incidence of myocardial infarction among patients treated for hypertension." American journal of public health 89, no. 9 (1999): 1414-1417
Katsanos, Aristeidis H., Angeliki Filippatou, Efstathios Manios, Spyridon Deftereos, John Parissis, et al. "Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials." Hypertension 69, no. 1 (2017): 171-179
PROGRESS Collaborative Group. "Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack." The Lancet 358, no. 9287 (2001): 1033-1041.
Burnier, Michel, and Aikaterini Damianaki. "Hypertension as cardiovascular risk factor in chronic kidney disease." Circulation research 132, no. 8 (2023): 1050-1063.
Klag, Michael J., Paul K. Whelton, Bryan L. Randall, James D. Neaton, Frederick L. Brancati, Charles E. Ford, Neil B. Shulman, and Jeremiah Stamler. "Blood pressure and end-stage renal disease in men." New England Journal of Medicine 334, no. 1 (1996): 13-18.
Lee, Haekyung, Soon Hyo Kwon, Jin Seok Jeon, Hyunjin Noh, Dong Cheol Han, and Hyoungnae Kim. "Association between blood pressure and the risk of chronic kidney disease in treatment-naïve hypertensive patients." Kidney research and clinical practice 41, no. 1 (2021): 31.
Sim, John J., Jiaxiao Shi, Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, and Steven J. Jacobsen. "Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population." Journal of the American College of Cardiology 64, no. 6 (2014): 588-597.
Pugh, Dan, Peter J. Gallacher, and Neeraj Dhaun. "Management of hypertension in chronic kidney disease." Drugs 79, no. 4 (2019): 365-379.
Hsu, Chi-yuan, Charles E. McCulloch, Jeanne Darbinian, Alan S. Go, and Carlos Iribarren. "Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease." Archives of internal medicine 165, no. 8 (2005): 923-928.
Hsu, Chi-yuan, Charles E. McCulloch, Jeanne Darbinian, Alan S. Go, and Carlos Iribarren. "Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease." Archives of internal medicine 165, no. 8 (2005): 923-928.
Abraham, Andrew T., Sanaullah Mojaddedi, Isaac H. Loseke, and Christopher Bray. "Hypertension in Patients With Peripheral Artery Disease: An Updated Literature Review." Cureus 16, no. 6 (2024).
Gallo, G. and Savoia, C., 2024. Hypertension and Heart Failure: From Pathophysiology to Treatment. International Journal of Molecular Sciences, 25(12), p.6661.
Parcha, Vibhu, Nirav Patel, Rajat Kalra, Joonseok Kim, Orlando M. Gutierrez, Garima Arora, and Pankaj Arora. "Incidence and implications of atrial fibrillation/flutter in hypertension: insights from the SPRINT trial." Hypertension 75, no. 6 (2020): 1483-1490.
Klein, R., and B. E. K. Klein. "Blood pressure control and diabetic retinopathy." British Journal of Ophthalmology 86, no. 4 (2002): 365-367.
Kim, Hae Rang, Nang Kyeong Lee, Christopher Seungkyu Lee, Suk Ho Byeon, Sung Soo Kim, Seung Won Lee, and Yong Joon Kim. "Retinal vascular occlusion risks in high blood pressure and the benefits of blood pressure control." American Journal of Ophthalmology 250 (2023): 111-119.
Ettehad, Dena, Connor A. Emdin, Amit Kiran, Simon G. Anderson, et al. "Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis." The Lancet 387, no. 10022 (2016): 957-967.
Carey, Robert M., Paul Muntner, Hayden B. Bosworth, and Paul K. Whelton. "Prevention and control of hypertension: JACC health promotion series." Journal of the American College of Cardiology 72, no. 11 (2018): 1278-1293.
Whelton, Paul K., Robert M. Carey, Wilbert S. Aronow, Donald E. Casey, Karen J. Collins, et al. "2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines." Journal of the American College of Cardiology 71, no. 19 (2018): e127-e248.
Williams, Bryan, Giuseppe Mancia, Wilko Spiering, Enrico Agabiti Rosei, Michel Azizi, Michel Burnier, Denis L. Clement et al. "2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)." European heart journal 39, no. 33 (2018): 3021-3104.
Zhu, Jiaying, Ning Chen, Muke Zhou, Jian Guo, Cairong Zhu, Jie Zhou, Mengmeng Ma, and Li He. "Calcium channel blockers versus other classes of drugs for hypertension." Cochrane Database of Systematic Reviews 10 (2021).
Lee, Eun Mi. "Calcium channel blockers for hypertension: Old, but still useful." Cardiovascular Prevention and Pharmacotherapy 5, no. 4 (2023): 113-125.
Ferreira, Rafael. "Thiazide diuretics in hypertension." E-Journal of the ESC Council for Cardiology Practice 35, no. 18 (2010).
Messerli, Franz H., Ehud Grossman, and Anthony F. Lever. "Do thiazide diuretics confer specific protection against strokes?." Archives of internal medicine 163, no. 21 (2003): 2557-2560.
Davis, Barry R., Linda B. Piller, Jeffrey A. Cutler, Curt Furberg, Kay Dunn, Stanley Franklin, David Goff et al. "Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial." Circulation 113, no. 18 (2006): 2201-2210
Salvetti, Antonio, and Lorenzo Ghiadoni. "Thiazide diuretics in the treatment of hypertension: an update." Journal of the American Society of Nephrology 17, no. 4_suppl_2 (2006): S25-S29.
Wald, David S., Malcolm Law, Joan K. Morris, Jonathan P. Bestwick, and Nicholas J. Wald. "Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials." The American journal of medicine 122, no. 3 (2009): 290-300.
UK, National Clinical Guideline Centre. "Hypertension: The Clinical Management of Primary Hypertension in Adults [Internet]." (2011).
Neal, B ∙ MacMahon, S ∙ Chapman, N, Effects of ACE inhibitors, calcium antagonists, and other blood- pressure-lowering drugs: results of prospectively designed overviews of randomised trials, Lancet. 2000; 356:1955-1964
Thomopoulos, Costas, Gianfranco Parati, and Alberto Zanchetti. "Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs–overview and meta-analyses." Journal of hypertension 33, no. 7 (2015): 1321-1341.
Heidenreich, Paul A., Tina T. Lee, and Barry M. Massie. "Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials." Journal of the American College of Cardiology 30, no. 1 (1997): 27-34.
Danesh, Arash, and P. Christopher H. Gottschalk. "Beta-blockers for migraine prevention: a review article." Current treatment options in neurology 21 (2019): 1-13.
Mancia, Giuseppe, Sverre E. Kjeldsen, Reinhold Kreutz, Atul Pathak, Guido Grassi, and Murray Esler. "Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines." Hypertension 79, no. 6 (2022): 1153-1166.
Alcocer, Luis Antonio, Alfonso Bryce, David De Padua Brasil, Joffre Lara, Javier Moreno Cortes, Daniel Quesada, and Pablo Rodriguez. "The pivotal role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension management and cardiovascular and renal protection: a critical appraisal and comparison of international guidelines." American Journal of Cardiovascular Drugs 23,6(2023): 663-682.
Beckett, Nigel S., Ruth Peters, Astrid E. Fletcher, Jan A. Staessen, Lisheng Liu, Dan Dumitrascu, Vassil Stoyanovsky et al. "Treatment of hypertension in patients 80 years of age or older." New England Journal of Medicine 358, no. 18 (2008): 1887-1898.
Lithell, Hans, Lennart Hansson, Ingmar Skoog, Dag Elmfeldt, Albert Hofman, Bertil Olofsson, Peter Trenkwalder, Alberto Zanchetti, and SCOPE Study Group. "The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial." Journal of hypertension 21, no. 5 (2003): 875-886.
Heart Outcomes Prevention Evaluation Study Investigators. "Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients." New England Journal of Medicine 342, no. 3 (2000): 145-153.
Dahlöf, Björn, Peter S. Sever, Neil R. Poulter, Hans Wedel, D. Gareth Beevers, Mark Caulfield, Rory Collins et al. "Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial." The Lancet 366, no. 9489 (2005): 895-906.
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. "Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial." The Lancet 372, no. 9644 (2008): 1174-1183.
Julius, Stevo, Sverre E. Kjeldsen, Michael Weber, Hans R. Brunner, Steffan Ekman, et al. "Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial." The Lancet 363, no. 9426 (2004): 2022-2031.
NAVIGATOR Study Group. "Effect of valsartan on the incidence of diabetes and cardiovascular events." New England Journal of Medicine 362, no. 16 (2010): 1477-1490.
Ontarget Investigators. "Telmisartan, ramipril, or both in patients at high risk for vascular events." New England Journal of Medicine 358, no. 15 (2008): 1547-1559.
European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. "Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)." The Lancet 362, no. 9386 (2003): 782-788.
PEACE Trial Investigators. "Angiotensin-converting–enzyme inhibition in stable coronary artery disease." New England Journal of Medicine 351, no. 20 (2004): 2058-2068.
Pitt, Bertram, Blair O’Neill, Robert Feldman, Roberto Ferrari, Leonard Schwartz, Harald Mudra, Theodore Bass et al. "The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function." The American journal of cardiology 87, no. 9 (2001): 1058-1063.
Pfeffer, Marc A., Eugene Braunwald, Lemuel A. Moyé, Lofty Basta, Edward J. Brown Jr, Thomas E. Cuddy, Barry R. Davis et al. "Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial." New England journal of medicine 327, no. 10 (1992): 669-677.
Swedberg, Karl, Peter Held, John Kjekshus, Knut Rasmussen, Lars Rydén, and Hans Wedel. "Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Stuy II (CONSENSUS II)." New England Journal of Medicine 327, no. 10 (1992): 678-684.
Study, The Acute Infarction Ramipril Efficacy AIRE. "Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure." The Lancet 342, no. 8875 (1993): 821-828.
Køber, Lars, Christian Torp-Pedersen, Jan E. Carlsen, Henning Bagger, Per Eliasen, Kjeld Lyngborg, Jørgen Videbæk et al. "A clinical trial of the angiotensin-converting–enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction." New England Journal of Medicine 333, no. 25 (1995): 1670-1676.
Ambrosioni, Ettore, Claudio Borghi, and Bruno Magnani. "The effect of the angiotensin-converting–enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction." New England Journal of Medicine 332, no. 2 (1995): 80-85.
Dickstein, Kenneth, and John Kjekshus. "Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial." The Lancet 360, no. 9335 (2002): 752-760.
Pfeffer, Marc A., John JV McMurray, Eric J. Velazquez, Jean-Lucien Rouleau, Lars Køber, Aldo P. Maggioni, Scott D. Solomon et al. "Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both." New England Journal of Medicine 349, no. 20 (2003): 1893-1906.
Consensus Trial Study Group*. "Effects of enalapril on mortality in severe congestive heart failure." New England Journal of Medicine 316, no. 23 (1987): 1429-1435.
SOLVD Investigators*. "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure." New England Journal of Medicine 325, no. 5 (1991): 293-302.
Granger, Christopher B., John JV McMurray, Salim Yusuf, Peter Held, Eric L. Michelson, Bertil Olofsson, Jan Östergren, Marc A. Pfeffer, and Karl Swedberg. "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial." The Lancet 362, no. 9386 (2003): 772-776.
Cohn, Jay N., and Gianni Tognoni. "A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure." New England Journal of Medicine 345, no. 23 (2001): 1667-1675.
Yusuf, Salim, Hans-Christoph Diener, Ralph L. Sacco, Daniel Cotton, Stephanie Ôunpuu, William A. Lawton, Yuko Palesch et al. "Telmisartan to prevent recurrent stroke and cardiovascular events." New England Journal of Medicine 359, no. 12 (2008): 1225-1237.
Patel, Anushka. "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial." The Lancet 370, no. 9590 (2007): 829-840.
Brenner, Barry M., Mark E. Cooper, Dick De Zeeuw, William F. Keane, William E. Mitch, Hans-Henrik Parving, Giuseppe Remuzzi, Steven M. Snapinn, Zhonxin Zhang, and Shahnaz Shahinfar. "Effectsa of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy." New England journal of medicine 345, no. 12 (2001): 861-869.
Lewis, Edmund J., Lawrence G. Hunsicker, William R. Clarke, Tomas Berl, Marc A. Pohl, Julia B. Lewis, Eberhard Ritz, Robert C. Atkins, Richard Rohde, and Itamar Raz. "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes." New England Journal of Medicine 345, no. 12 (2001): 851-860.
arving, Hans-Henrik, Hendrik Lehnert, Jens Bröchner-Mortensen, Ramon Gomis, Steen Andersen, and Peter Arner. "The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes." New England Journal of Medicine 345, no. 12 (2001): 870-878.
Imai, E., J. C. N. Chan, S. F. Ito, T. Yamasaki, F. Kobayashi, M. Haneda, H. Makino, and ORIENT Study Investigators. "Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study." Diabetologia 54 (2011): 2978-2986.
Haller, Hermann, Sadayoshi Ito, Joseph L. Izzo Jr, Andrzej Januszewicz, Shigehiro Katayama, Jan Menne, Albert Mimran et al. "Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes." New England Journal of Medicine 364, no. 10 (2011): 907-917.
Carey, Robert M., David A. Calhoun, George L. Bakris, Robert D. Brook, Stacie L. Daugherty, Cheryl R. Dennison-Himmelfarb, Brent M. Egan et al. "Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association." Hypertension 72, no. 5 (2018): e53-e90.
Calhoun, David A., Daniel Jones, Stephen Textor, David C. Goff, Timothy P. Murphy, Robert D. Toto, Anthony White et al. "Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research." Hypertension 51, no. 6 (2008): 1403-1419
Williams, Bryan, Giuseppe Mancia, Wilko Spiering, Enrico Agabiti Rosei, Michel Azizi, et al. "2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension." Blood pressure 27, no. 6 (2018): 314-340
Williams, Bryan, Thomas M. MacDonald, Steve Morant, David J. Webb, Peter Sever, Gordon McInnes, Ian Ford et al. "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial." The Lancet 386, no. 10008 (2015): 2059-2068
Basile, Jan N. "One size does not fit all: the role of vasodilating β-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk." The American journal of medicine 123, no.7 (2010): S9-S15
Miranda, Roberto Dischinger, Décio Mion Jr, Joăo Carlos Rocha, Oswaldo Kohlmann Jr, Marco Antonio Mota Gomes, José Francisco Kerr Saraiva, Celso Amodeo, and Bráulio Luna Filho. "An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study." Clinical therapeutics 30, no. 9 (2008): 1618-1628.
Downloads
Published
How to Cite
Issue
Section
